Activin and Inhibin

AF38469 is a selective, orally bioavailable Sortilin inhibitor with an IC 50 value of 330 nM.In VivoAF38469 (1 mg/kg: i.v.) has a low volume of distribution (blood volume of 0.7 L/kg) and low clearance (4.8 L/h/kg), and a half-life (t1/2) of 1.2 h

AF38469 is a selective, orally bioavailable Sortilin inhibitor with an IC 50 value of 330 nM.In VivoAF38469 (1 mg/kg: i.v.) has a low volume of distribution (blood volume of 0.7 L/kg) and low clearance (4.8 L/h/kg), and a half-life (t1/2) of 1.2 h

AF38469 is a selective, orally bioavailable Sortilin inhibitor with an IC 50 value of 330 nM.In VivoAF38469 (1 mg/kg: i.v.) has a low volume of distribution (blood volume of 0.7 L/kg) and low clearance (4.8 L/h/kg), and a half-life (t1/2) of 1.2 h

AF40431, the first reported small-molecule ligand of sortilin, has an IC 50 of 4.4 µM and a K d of 0.7 µM . AF40431 is bound in the neurotensin-binding site of sortilinForm:SolidIC50&amp: Target:IC50: 4.4 µM (sortilin)/nKd: 0.7 µM (sortilin).

AF40431, the first reported small-molecule ligand of sortilin, has an IC 50 of 4.4 µM and a K d of 0.7 µM . AF40431 is bound in the neurotensin-binding site of sortilinForm:SolidIC50&amp: Target:IC50: 4.4 µM (sortilin)/nKd: 0.7 µM (sortilin).

AF40431, the first reported small-molecule ligand of sortilin, has an IC 50 of 4.4 µM and a K d of 0.7 µM . AF40431 is bound in the neurotensin-binding site of sortilinForm:SolidIC50&amp: Target:IC50: 4.4 µM (sortilin)/nKd: 0.7 µM (sortilin).

AF40431, the first reported small-molecule ligand of sortilin, has an IC 50 of 4.4 µM and a K d of 0.7 µM . AF40431 is bound in the neurotensin-binding site of sortilinForm:SolidIC50&amp: Target:IC50: 4.4 µM (sortilin)/nKd: 0.7 µM (sortilin).

AF40431, the first reported small-molecule ligand of sortilin, has an IC 50 of 4.4 µM and a K d of 0.7 µM . AF40431 is bound in the neurotensin-binding site of sortilinForm:SolidIC50&amp: Target:IC50: 4.4 µM (sortilin)/nKd: 0.7 µM (sortilin).

AF40431, the first reported small-molecule ligand of sortilin, has an IC 50 of 4.4 µM and a K d of 0.7 µM . AF40431 is bound in the neurotensin-binding site of sortilinForm:SolidIC50&amp: Target:IC50: 4.4 µM (sortilin)/nKd: 0.7 µM (sortilin).

Afizagabar (S44819) is a first-in-class, competitive, and selective antagonist at the GABA-binding site of the α5-GABAAR , with an IC 50 of 585 nM for α5β2γ2 and a K i of 66 nM for α5β3γ2. Afizagabar enhances hippocampal synaptic plasticity and

Afizagabar (S44819) is a first-in-class, competitive, and selective antagonist at the GABA-binding site of the α5-GABAAR , with an IC 50 of 585 nM for α5β2γ2 and a K i of 66 nM for α5β3γ2. Afizagabar enhances hippocampal synaptic plasticity and

Afizagabar (S44819) is a first-in-class, competitive, and selective antagonist at the GABA-binding site of the α5-GABAAR , with an IC 50 of 585 nM for α5β2γ2 and a K i of 66 nM for α5β3γ2. Afizagabar enhances hippocampal synaptic plasticity and